인간 마이크로바이옴 시장 : 업계 동향과 세계 예측 - 제품 유형별, 분자 유형별, 표적 적응증별, 치료 영역별, 투여 경로별, 주요 지역별

Human Microbiome Market Distribution : Industry Trends and Global Forecasts by Type of Product, Type of Molecule, Target Indication, Therapeutic Area, Route of Administration and Key Geographical Regions

US $ 4,799 ￦ 6,650,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999 ￦ 9,699,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599 ￦ 14,688,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999 ￦ 24,943,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

인간 마이크로바이옴 시장 : 개요

세계의 인간 마이크로바이옴 시장 규모는 2035년까지의 예측 기간 중 20.4%의 CAGR로 확대하며, 현재 7억 9,100만 달러에서 2035년까지 60억 9,100만 달러로 성장할 것으로 예측됩니다.

시장 세분화에서는 시장 규모와 시장 기회를 다음과 같은 매개 변수로 구분합니다.

제품 유형

• 프로바이오틱스 의약품
• 기타

분자 유형

• 저분자
• 생물제제

표적 적응증

• 대장암
• 당뇨병
• 염증성 장질환
• 과민성 대장 증후군
• 이식편 대 숙주병
• 괴사성 장염
• 원발성 고산소뇨증
• 재발성 CDI

치료 영역

• 소화기 및 위장질환
• 감염성 질환
• 대사성 질환
• 종양학 질환
• 희귀질환

투여 경로

• 경구
• 직장

주요 지역

• 북미
• 유럽
• 아시아태평양
• 기타 지역

인간 마이크로바이옴 시장 : 성장과 동향

미생물이라고 하면 과거에는 유해한 질병의 원인 물질이라는 이미지가 강했으나, 인체 내에서 특정 유익한 미생물 군집이 발견되었습니다. 인간과 세균, 효모, 원생동물 등 다양한 미생물 종은 상호 유익한 관계로 공존하는 것으로 알려져 있습니다. 또한 인간의 장내 미생물은 약 100조 개의 미생물로 구성되어 있는 것으로 추정되고 있습니다. 주목할 만한 점은 이 수치가 인체의 총 세포 수를 크게 상회한다는 점입니다.

대부분의 미생물은 다른 방법으로는 얻을 수 없는 형질과 능력을 부여함으로써 인간에게 큰 이익을 가져다 줍니다. 장내세균의 건강한 다양성은 면역력을 높이고 광범위한 건강상의 이점을 제공할 수 있는 큰 잠재력을 가지고 있습니다. 이에 따라 인간 마이크로바이옴을 기반으로 한 살아있는 바이오 치료제/진단제 개발 업체들의 광범위한 연구개발 노력이 이루어지고 있으며, 독자적인 제품 후보물질의 임상 진전이라는 측면에서 큰 진전을 이루고 있습니다. 또한 인간 마이크로바이옴과 건강의 밀접한 연관성으로 인해 상재 미생물의 조작을 기반으로 한 수많은 치료적 개입이 개발되고 있습니다.

인간 마이크로바이옴 시장 : 주요 인사이트

이 보고서는 인간 마이크로바이옴 시장 현황을 조사하고 업계내 잠재적인 성장 기회를 파악합니다. 이 보고서의 주요 조사 결과는 다음과 같습니다.

• 현재 전 세계 70여개 기업이 인간 마이크로바이옴을 조작하는 치료제 개발에 매진하고 있습니다.
• 파이프라인에는 230개 이상의 인간 마이크로바이옴 치료제가 있으며, 현재 다양한 개발 단계에서 평가되고 있습니다.
• 파이프라인 의약품의 약 30%가 임상 개발 단계에 있으며, 150개 이상의 의약품이 전임상 및 탐색 단계에 있습니다. 임상 단계에 있는 의약품은 주로 감염성 질환과 소화기 질환을 대상으로 개발되고 있으며, 전임상 및 탐색 단계에 있는 후보 의약품은 암 질환을 대상으로 하고 있습니다.
• 현재 전 세계 40개 이상의 기업이 질병을 감지하고 인체 미생물총의 구성과 기능을 분석하기 위한 다양한 진단약과 스크리닝/프로파일링 검사 키트를 제공합니다.
• 75개 이상의 진단약 및 스크리닝/프로파일링 검사가 사용 가능/개발 중입니다.

이 중 약 80%는 시장에서 사용 가능하며, 나머지는 개발 중에 있습니다.

• 현재 시중에는 70개 이상의 마이크로바이옴에 초점을 맞춘 진단 및 스크리닝/프로파일링 검사가 출시되어 있습니다. 이러한 검사 키트는 다양한 치료 영역에 걸쳐 다양한 샘플 유형을 검사할 수 있습니다.

• 현재 시판 중인 마이크로바이옴 관련 제품은 FMT가 유일합니다. 실제로 지난 10년간 업계 외의 기업이 후원하여 FMT를 평가하는 임상시험이 400건 이상 등록되어 있습니다.
• 자금력을 갖춘 몇몇 스타트업들도 이 분야에 뛰어들고 있습니다. 당사의 자체 스타트업 건강지표 분석 결과, 마이크로바이옴 치료제 개발에 큰 기대를 걸고 있는 기업이 다수 존재함을 확인했습니다.
• 이러한 관심은 과거 다양한 이해관계자들 간에 맺어진 폭넓은 파트너십에도 반영되어 있습니다.
• 이 분야의 파트너십 활동은 2017년 이후 CAGR 26%로 증가했습니다. 이 기간 중 체결된 파트너십의 35% 이상을 차지하는 R&D 계약이 대부분을 차지했다는 점은 주목할 만합니다.
• 다양한 질병 치료에 있으며, 마이크로바이옴 치료제의 장점과 미래 잠재력을 알아본 수많은 투자자들이 2019년 이후 10억 달러 이상을 스타트업에 투자했습니다.
• 총 투자액 중 5억 6,300만 달러 이상이 벤처캐피털을 통한 자금 조달로, 이 분야 전체 자금 조달 활동의 56% 이상을 차지했습니다. 또한 36건의 보조금/수상도 보고되었으며, 참가 기업은 총 1억 3,700만 달러 이상의 자금을 조달했습니다.
• 25개 이상의 업계 기업이 다양한 치료 목적의 미생물 기반 생물제제 제조에 종사하고 있다고 주장하고 있으며, 이들 기업의 대부분은 유럽에 본사를 두고 있습니다.
• 현재 진행 중인 연구와 발전에 힘입어 인간 마이크로바이옴 치료제 및 진단 시장은 향후 수년간 큰 속도로 성장할 것으로 예측됩니다.
• 특히 인간 마이크로바이옴 치료제 시장은 CAGR 20.4%를 보일 것으로 예측되며, 그 기회는 다양한 제품, 치료 분야, 지역으로 잘 분산될 것으로 보입니다.

• 향후 10년간 마이크로바이옴 진단제 시장은 다양한 공급 채널을 통해 연간 53%의 성장률을 보일 것으로 예측됩니다.
• 후기 단계의 치료제가 FDA 승인을 받을 것으로 예상에 따라 마이크로바이옴 치료제는 2035년까지 전체 마이크로바이옴 시장의 60% 이상의 점유율을 차지할 것으로 예측됩니다.

인간 마이크로바이옴 시장의 참여 기업 예

• 4D Pharma
• Biosotia Microbiomics
• DNA Genotek
• Finch Therapeutics
• GoodGut
• Infant Bacterial Therapeutics
• Invivo Healthcare
• MaaT Pharma
• OxThera
• Qu Biologics
• Rebiotix
• Seres Therapeutics
• Servatus
• Shoreline Biome

목차

제1장 서문

제2장 개요

제3장 서론

• 챕터 개요
• 미생물총과 마이크로바이옴의 개념
• 장내 플로라의 개요
• 마이크로바이옴과 관련 질환
• 미생물총별 약물 동태에 대한 영향
• 미생물총이 치료 결과에 미치는 영향
• 마이크로바이옴 치료제
• 인간 마이크로바이옴 프로젝트(HMP)
• 생바이오의약품(LBP)에 관한 규제 가이드라인
• 마이크로바이옴 치료제의 개발에 수반하는 주요 과제
• 향후 전망

제4장 마이크로바이옴 치료제 : 시장 구도

• 챕터 개요
• 마이크로바이옴 치료제 : 임상 파이프라인
• 마이크로바이옴 치료제 : 전임상 파이프라인
• 마이크로바이옴 치료제 : 의약품 개발자 리스트

제5장 마이크로바이옴 치료제 : 기업과 약제 개요

• 챕터 개요
• 마이크로바이옴 치료제 개발 기업 : 개발 단계가 가장 진행되고 있는 후보 제품을 가진 기업
• Finch Therapeutics
• Infant Bacterial Therapeutics
• MaaT Pharma
• OxThera
• Rebiotix
• Seres Therapeutics
• 마이크로바이옴 치료제 개발 기업 : 치료 프로그램 수가 가장 많은 기업
• 4D Pharma
• Biosortia Pharmaceuticals
• Qu Biologics
• Servatus

제6장 임상시험 분석 : 인간 마이크로바이옴 치료제

• 챕터 개요
• 인간 마이크로바이옴 치료제 : 임상시험 리스트

제7장 마이크로바이옴 진단 및 스크리닝/프로파일링 검사 : 시장 구도

• 챕터 개요
• 마이크로바이옴 진단과 스크리닝/프로파일링 검사의 개요
• 마이크로바이옴 진단 및 스크리닝/프로파일링 검사 : 시판 및 개발중인 제품
• 마이크로바이옴 진단 및 스크리닝/프로파일링 검사 프로바이더

제8장 마이크로바이옴 진단 및 스크리닝/프로파일링 검사 프로바이더 : 기업 개요

• 챕터 개요
• Shoreline Biome
• DNA Genotek
• Invivo Healthcare
• GoodGut
• BiomeDx

제9장 분변 미생물 이식(FMT)

• 챕터 개요
• 분변 미생물 이식(FMT) 서론
• 역사적 개요
• 분변 미생물 이식 : 시술과 임상적 의의
• 분변 미생물 이식에 관한 규제 가이드라인
• 분변 미생물 이식의 보험 적용
• 분변 미생물 이식 : 출시 및 개발 파이프라인

제10장 임상시험 분석 : 분변 미생물 이식

• 챕터 개요
• 범위와 조사 방법
• 분변 미생물 이식 : 임상시험 분석

제11장 매력과 경쟁력(AC) 매트릭스

• 챕터 개요
• AC 매트릭스 : 개요
• AC 매트릭스 : 분석 조사 방법
• AC 매트릭스 : 정보 플롯
• AC 매트릭스 : 데이터의 분석
• 결론

제12장 대형 제약회사의 마이크로바이옴 관련 구상

• 챕터 개요
• 범위와 조사 방법
• 대형 제약회사의 구상
• 대형 제약회사의 벤치마킹 분석

제13장 스타트업 건전성 지표

• 챕터 개요
• 범위와 조사 방법
• 스타트업의 벤치마킹

제14장 주요 치료 영역

• 챕터 개요
• 대사장애
• 소화기계 및 위장계 질환
• 종양학적 적응증
• 피부 질환
• 감염증

제15장 파트너십과 협업

제16장 자금조달과 투자 분석

• 챕터 개요
• 자금조달의 유형
• 마이크로바이옴 치료·진단 : 자금조달과 투자 리스트

제17장 사례 연구 : 마이크로바이옴 치료제 및 생체 바이오 치료제 계약 서비스

• 챕터 개요
• 마이크로바이옴 치료제의 제조
• CMO/CRO 파트너 선택시 고려해야 할 중요한 점

제18장 빅데이터와 마이크로바이옴 치료

• 챕터 개요
• 빅데이터 서론
• 사물인터넷(IoT)
• 빅데이터에 대한 관심의 증가 : Google 동향 분석
• 주요 용도
• 마이크로바이옴 조사에서의 빅데이터
• 마이크로바이옴 조사의 빅데이터 서비스 : 기업 리스트
• 마이크로바이옴 조사의 빅데이터 서비스 : 주요 진출 기업의 개요

제19장 마이크로바이옴 치료제 : 시장 예측과 기회 분석

• 챕터 개요
• 주요 전제
• 예측 조사 방법
• 2035년까지의 세계 마이크로바이옴 치료제 시장

제20장 마이크로바이옴 진단 : 시장 예측과 기회 분석

• 챕터 개요
• 범위와 제한
• 예측 조사 방법
• 세계의 인간 마이크로바이옴 진단 검사 시장(-2035년)

제21장 분변 미생물 이식 : 시장 예측과 기회 분석

• 챕터 개요
• 예측 조사 방법과 주요 전제조건
• 세계의 분변 미생물 이식 시장(-2035년)
• 마이크로바이옴 시장 전체(제품별, 2035년까지)

제22장 사례 연구 : 비의약품 산업에서 마이크로바이옴 기반 제품

• 챕터 개요
• 비의약품 업계에서 마이크로바이옴 제품의 리스트
• 농업 산업에서 마이크로바이옴 기반 제품의 응용
• 향후 전망

제23장 결론

제24장 이그제큐티브 인사이트

제25장 부록 I : 표형식 데이터

제26장 부록 II : 기업 및 조직 리스트

KSA

영문 목차

영문목차

HUMAN MICROBIOME MARKET: OVERVIEW

As per Roots Analysis, the global human microbiome market is estimated to grow from USD 791 million in the current year to USD 6,091 million by 2035, at a CAGR of 20.4% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Product

• Probiotic Drugs
• Other Drugs

Type of Molecule

• Small Molecules
• Biologics

Target Indication

• Colorectal Cancer
• Diabetes Mellitus
• Inflammatory Bowel Disease
• Irritable Bowel Syndrome
• Graft vs. Host Disease
• Necrotizing Enterocolitis
• Primary Hyperoxaluria
• Recurrent CDI

Therapeutic Area

• Digestive and Gastrointestinal Disorders
• Infectious Diseases
• Metabolic Disorders
• Oncological Disorders
• Rare Disorders

Route of Administration

• Oral
• Rectal

Key Geographical Regions

• North America
• Europe
• Asia-Pacific
• Rest of the World

HUMAN MICROBIOME MARKET: GROWTH AND TRENDS

The term microorganism were previously associated with harmful disease-causing agents, until the discovery of certain beneficial microbial colonies in the human system. Humans and a variety of microbial species of bacteria, yeast and protozoa, are known to co-exist in mutually beneficial relationships. Moreover, it is estimated that the human gut microbiome consists of about 100 trillion microorganisms. Notably, this figure significantly outnumbers the total number of cells in the human body.

The majority of microorganisms provide significant benefits to humans by conferring traits and capabilities that would otherwise be absent. The healthy variety of bacteria in the gut has significant potential to enhance immunity and offer a wide range of health benefits. This has led to extensive research and development efforts by human microbiome based live biotherapeutics / diagnostic developers to make significant strides, in terms of progressing proprietary product candidates into the clinic. In addition, owing to the strong association between the human microbiome and health, a myriad of therapeutic interventions based on manipulation of commensal microbes are under development.

HUMAN MICROBIOME MARKET: KEY INSIGHTS

The report delves into the current state of the human microbiome market and identifies potential growth opportunities within industry. Some key findings from the report include:

• Presently, over 70 companies, worldwide, have taken initiatives to develop therapies that can manipulate the human microbiome; the market is characterized by the presence of small companies.
• The pipeline features 230+ human microbiome therapeutics that are currently being evaluated across different phases of development; the majority of these are designed for oral delivery.
• Nearly 30% of the pipeline drugs are in clinical phase of development, while more than 150 drugs are in preclinical and discovery stages. Clinical stage drugs are primarily being developed for infectious diseases and digestive disorders, while candidates in preclinical and discovery stages are focused on oncological disorders.
• Currently, over 40 companies, worldwide, are engaged in providing various diagnostics and screening / profiling test kits for the purpose of disease detection and analysis of human microflora composition and function.
• More than 75 diagnostics and screening / profiling test are available / under development.

Of these, around 80% of the tests are available in the market, while rest are under development.

• Over 70 microbiome focused diagnostic and screening / profiling tests are available in the market; such test kits allow testing of different sample types across various therapeutic areas.

• Presently, FMTs are the only commercially available microbiome product; in fact, more than 400 clinical trials evaluating FMTs, sponsored by non-industry players, have been registered in the past decade.
• Several well-funded start-ups have entered this domain; our proprietary start-up health indexing analysis confirms the presence of a number of players that offer significant promise in developing microbiome therapeutics.
• The rising interest is also reflected in the wide array of partnerships being established between various stakeholders in the recent past; research agreements emerged as the most popular type of partnership model.
• Partnership activity in this domain increased at a CAGR of 26%, since 2017. It is worth highlighting that majority of the deals were R&D agreements, representing over 35% of the total number of partnerships signed in the given time period.
• Numerous investors, having realized the benefits and future opportunities of microbiome therapeutics in the treatment of various disorders, have invested more than USD 1 billion in start-ups, since 2019.
• Of the total amount invested, over USD 563 million was raised through venture capital financing, representing over 56% of the overall funding activity in this domain. Further, 36 instances of grants / awards were also reported, wherein players collectively raised more than USD 137 million.
• More than 25 industry players claim to be engaged in the manufacturing of microbiome-based biologics for various therapeutic purposes; majority of these firms are headquartered in Europe.
• Driven by ongoing research and advancements, the human microbiome therapeutics and diagnostics market is anticipated to grow at a significant pace in the coming years.
• Specifically, the human microbiome therapeutics market is anticipated to grow at a CAGR of 20.4%; the opportunity is likely to be well-distributed across different products, therapeutic areas and geographies.

• In the coming decade, we anticipate the opportunity for microbiome diagnostics market to grow at an annualized rate of ~53% across different supply channels.
• As late-stage therapeutics will get approved by the FDA in the foreseen future, microbiome therapeutics are anticipated to capture more than 60% share of total microbiome market by 2035.

Example Players in the Human Microbiome Market

• 4D Pharma
• Biosotia Microbiomics
• DNA Genotek
• Finch Therapeutics
• GoodGut
• Infant Bacterial Therapeutics
• Invivo Healthcare
• MaaT Pharma
• OxThera
• Qu Biologics
• Rebiotix
• Seres Therapeutics
• Servatus
• Shoreline Biome

HUMAN MICROBIOME MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global human microbiome market, focusing on key market segments, including [A] type of product, [B] type of molecule, [C] target indication, [D] therapeutic area, [E] route of administration and [F] key geographical regions.
• Microbiome Therapeutics Market Landscape: A comprehensive evaluation of microbiome therapeutics, based on several relevant parameters, such as [A] phase of development of product candidates, [B] type of molecule, [C] type of therapy, [D] target indication(s), [E] therapeutic area(s), [F] route of administration, [G] type of drug formulation, [H] type of microbiome therapy, [I] combination drug, [J] dosing frequency and [K] special drug designations (if any). Additionally, a comprehensive evaluation of the microbiome companies engaged in the development of microbiome therapeutics, based on several relevant parameters, such as [A] year of establishment, [B] company size and [C] location of headquarters.
• Microbiome Therapeutics Company and Drug Profiles: In-depth profiles of key players that are currently engaged in the development of microbiome therapeutics, focusing on [A] overview of the company, [B] financial information (if available) [C] microbiome-based drug portfolio, [D] information on clinical trial and [E] recent developments and an informed future outlook. Additionally, in-depth profiles of key players that are currently engaged in more than six therapeutic programs, focusing on [A] overview of the company, [B] financial information (if available), [C] drug portfolio and [D] informed future outlook.
• Microbiome Diagnostics and Screening / Profiling Tests Market Landscape: A comprehensive evaluation of various types of microbiome diagnostic and screening / profiling tests, based on several relevant parameters, such as [A] stage of development, [B] type of sample analyzed, [C] type of screening technique. [D] target indication(s), [E] key therapeutic area(s) and [F] purpose of diagnosis. Additionally, a comprehensive evaluation of diagnostics and screening / profiling test providers(s), based on several relevant parameters, such as [A] year of establishment, [B] company size and [C] location of headquarters.
• Microbiome Diagnostics and Screening / Profiling Tests Providers Company Profiles: In-depth profiles of key players that are currently engaged in the development of microbiome diagnostics and screening / profiling tests, focusing on [A] overview of the company, [B] financial information (if available) [C] diagnostic or screening / profiling test portfolio and [D] recent developments and an informed future outlook.
• Clinical Trial Analysis: An insightful analysis of clinical trials related to fecal transplant, based on several parameters, such as [A] trial status, [B] trial registration year, [C] trial phase, [D] year-wise trend of completed and recruiting trials, [E] study design, [F] number of patients enrolled, [G] age category of the patients enrolled, [H] type of sponsor / collaborator, [I] active industry and non-industry players, and [J] location of the trials. Furthermore, an insightful analysis of various stool banks based on [A] year of establishment and [B] location of headquarters, along with brief profiles of the most prominent stool banks located across the globe.
• Attractiveness Competitiveness (AC) Matrix: A comprehensive business portfolio analysis based on an attractiveness and competitiveness (AC) framework, featuring the current market attractiveness and competition across the most popular disease indication(s) for which microbiome therapeutics are under investigation.
• Start-Up Health Indexing: An assessment of the start-ups / small-sized players that are engaged in the development of microbiome therapeutics and diagnostics, based on relevant parameters, such as [A] number of microbiome therapeutics under development, [B] diversity of product portfolio, [C] funding amount, [D] partnership activity and [E] disease indication(s) being treated.
• Key Therapeutic Areas: In-depth analysis of the most commonly targeted therapeutic indications and information on microbiome-based drugs that are being developed against them, based on [A] key epidemiological facts about specific diseases, [B] available methods of diagnosis and [C] currently available treatment options and their side effects.
• Partnerships and Collaborations: An insightful analysis of the deals inked by stakeholders in the human microbiome market, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] type of product, [D] target indication, [E] therapeutic area, [F] type of company, [G] type of partner, [H] most active players and [I] geographical distribution of the partnership activity.
• Funding and Investments: An in-depth analysis of the fundings raised by human microbiome companies, based on relevant parameters, such as [A] year of investment, [B] amount invested, [C] type of funding, [D] type of company, [E] purpose of funding, [F] type of product, [G] target indication, [H] therapeutic area, [I] geographical analysis, [J] most active players and [K] most active investors.
• Case Study: A detailed discussion on the various steps involved in the development and manufacturing of microbiome therapeutics, along with information of contract manufacturers, focusing on [A] year of establishment, [B] location of headquarters, [C] company size, [D] scale of operation, [E] type of product manufactured and [F] type of formulation. Additionally, a detailed discussion on the key considerations that are required for selecting a CMO / CRO partner.
• Big Data and Microbiome Therapeutics: A comprehensive assessment of the emerging role of big data, representing efforts made to develop and implement various algorithms / tools to analyze data generated from microbiome research. Further, a detailed google trends analysis demonstrating a rising interest in stakeholders to use big data tools for supporting microbiome research over the past decade.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Scope of the Report
• 1.2. Research Methodology
  • 1.2.1. Research Assumptions
  • 1.2.2. Project Methodology
  • 1.2.3. Forecast Methodology
  • 1.2.4. Robust Quality Control
  • 1.2.5. Key Considerations
    • 1.2.5.1. Demographics
    • 1.2.5.2. Economic Factors
    • 1.2.5.3. Government Regulations
    • 1.2.5.4. Supply Chain
    • 1.2.5.5. COVID Impact / Related Factors
    • 1.2.5.6. Market Access
    • 1.2.5.7. Healthcare Policies
    • 1.2.5.8. Industry Consolidation
• 1.3 Key Questions Answered
• 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

• 3.1. Chapter Overview
• 3.2. Concept of Microbiota and Microbiome
  • 3.2.1. Discovery of the Human Microbiome
  • 3.2.2. Functions of the Human Microbiome
• 3.3. Overview of Gut Flora
  • 3.3.1. Role of Gut Flora in Human Health
  • 3.3.2. Factors Affecting Gut Flora
    • 3.3.2.1. Antibiotic Consumption
    • 3.3.2.2. Age and Pregnancy
      • 3.3.2.2.1. Mode of Childbirth
      • 3.3.2.2.2. Type of Feeding
      • 3.3.2.2.3. Antibiotic Consumption by Mother
    • 3.3.2.3. Stress-related Factors
    • 3.3.2.4. Dietary Factors
    • 3.3.2.5. Impact of Lifestyle
• 3.4. Microbiome and Associated Diseases
  • 3.4.1. Cancer
  • 3.4.2. Inflammatory Bowel Disease (IBD)
  • 3.4.3. Obesity
  • 3.4.4. Parkinson's Disease
  • 3.4.5. Type 2 Diabetes
  • 3.4.6. Other Disease Indications
• 3.5. Impact of Microbiota on Drug Pharmacokinetics
• 3.6. Impact of Microbiota on Therapeutic Outcomes
• 3.7. Microbiome Therapeutics
  • 3.7.1. Probiotics
    • 3.7.1.1. Beneficial Bacterial Strains
      • 3.7.1.1.1. Lactobacilli
      • 3.7.1.1.2. Bifidobacteria
      • 3.7.1.1.3. Others
    • 3.7.1.2. Key Therapeutic Areas
      • 3.7.1.2.1. Antibiotic-Associated Diarrhea (AAD)
      • 3.7.1.2.2. Bacterial Vaginosis
      • 3.7.1.2.3. High Blood Pressure
      • 3.7.1.2.4. Hypercholesterolemia
      • 3.7.1.2.5. Infectious Childhood Diarrhea (ICD)
      • 3.7.1.2.6. Inflammatory Bowel Disease (IBD)
      • 3.7.1.2.7. Lactose Intolerance
      • 3.7.1.2.8. Vitamin Production
      • 3.7.1.2.9. Weight Management
    • 3.7.1.3. Side Effects of Probiotics
  • 3.7.2. Prebiotics
    • 3.7.2.1. Sources of Prebiotics
    • 3.7.2.2. Types of Prebiotics
      • 3.7.2.2.1. Fructo-Oligosaccharides (FOS)
      • 3.7.2.2.2. Galacto-Oligosaccharides (GOS)
      • 3.7.2.2.3. Inulin
    • 3.7.2.3. Key Therapeutic Areas
      • 3.7.2.3.1. Antibiotic Associated Diarrhea (AAD)
      • 3.7.2.3.2. Constipation
      • 3.7.2.3.3. Gastrointestinal Diseases
      • 3.7.2.3.4. Dysbiosis
    • 3.7.2.4. Side Effects of Prebiotics
• 3.8. The Human Microbiome Project (HMP)
  • 3.8.1. Project Approach
  • 3.8.2. Project Initiatives
  • 3.8.3. Project Achievements
• 3.9. Regulatory Guidelines for Live Biotherapeutic Products (LBPs)
• 3.10. Key Challenges Associated with the Development of Microbiome Therapeutics
• 3.11. Future Perspectives

4. MICROBIOME THERAPEUTICS: MARKET LANDSCAPE

• 4.1. Chapter Overview
• 4.2. Microbiome Therapeutics: Clinical Pipeline
  • 4.2.1. Analysis by Phase of Development
  • 4.2.2. Analysis by Type of Molecule
  • 4.2.3. Analysis by Phase of Development and Type of Molecule
  • 4.2.4. Analysis by Type of Biologic
  • 4.2.5. Analysis by Type of Product
  • 4.2.6. Analysis by Target Indication
  • 4.2.7. Analysis by Therapeutic Area
  • 4.2.8. Analysis by Route of Administration
  • 4.2.9. Analysis by Type of Formulation
  • 4.2.10. Analysis by Dose Frequency
  • 4.2.11. Analysis by Type of Therapy
  • 4.2.12. Analysis by Combination Drug
• 4.3. Microbiome Therapeutics: Preclinical Pipeline
  • 4.3.1. Analysis by Phase of Development
  • 4.3.2. Analysis by Type of Molecule
  • 4.3.3. Analysis by Phase of Development and Type of Molecule
  • 4.3.4. Analysis by Type of Biologic
  • 4.3.5. Analysis by Type of Product
  • 4.3.6. Analysis by Target Indication
  • 4.3.7. Analysis by Therapeutic Area
  • 4.3.8. Analysis by Route of Administration
• 4.4. Microbiome Therapeutics: List of Drug Developers
  • 4.4.1. Analysis by Year of Establishment
  • 4.4.2. Analysis by Company Size
  • 4.4.3. Analysis by Location of Headquarters
  • 4.4.4. Analysis by Company Size and Location of Headquarters

5. MICROBIOME THERAPEUTICS: COMPANY AND DRUG PROFILES

• 5.1. Chapter Overview
• 5.2. Microbiome Therapeutics Developers: Companies with Candidate(s) in Highest Phase of Development
• 5.3. Finch Therapeutics
  • 5.3.1. Company Overview
  • 5.3.2. Microbiome-Based Product Portfolio
    • 5.3.2.1. CP101
      • 5.3.2.1.1. Drug Overview
      • 5.3.2.1.2. Current Status of Development
      • 5.3.2.1.3. Clinical Studies
  • 5.3.3. Recent Developments and Future Outlook
• 5.4. Infant Bacterial Therapeutics
  • 5.4.1. Company Overview
  • 5.4.2. Microbiome-Based Product Portfolio
    • 5.4.2.1. IBP-9414
      • 5.4.2.1.1. Drug Overview
      • 5.4.2.1.2. Current Status of Development
      • 5.4.2.1.3. Clinical Studies
  • 5.4.3. Recent Developments and Future Outlook
• 5.5. MaaT Pharma
  • 5.5.1. Company Overview
  • 5.5.2. Microbiome-Based Product Portfolio
    • 5.5.2.1. MaaT013
      • 5.5.2.1.1. Drug Overview
      • 5.5.2.1.2. Current Status of Development
      • 5.5.2.1.3. Clinical Studies
  • 5.5.3. Recent Developments and Future Outlook
• 5.6. OxThera
  • 5.6.1. Company Overview
  • 5.6.2. Microbiome-Based Product Portfolio
    • 5.6.2.1. Oxabact
      • 5.6.2.1.1. Drug Overview
      • 5.6.2.1.2. Current Status of Development
      • 5.6.2.1.3. Clinical Studies
  • 5.6.3. Recent Developments and Future Outlook
• 5.7. Rebiotix (acquired by Ferring Pharmaceuticals)
  • 5.7.1. Company Overview
  • 5.7.2. Financial Information
  • 5.7.3. Microbiome-Based Product Portfolio
    • 5.7.3.1. RBX2660
      • 5.7.3.1.1. Drug Overview
      • 5.7.3.1.2. Current Status of Development
      • 5.7.3.1.3. Clinical Studies
  • 5.7.4. Recent Developments and Future Outlook
• 5.8. Seres Therapeutics
  • 5.8.1. Company Overview
  • 5.8.2. Financial Information
  • 5.8.3. Microbiome-Based Product Portfolio
    • 5.8.3.1. SER-109
      • 5.8.3.1.1. Drug Overview
      • 5.8.3.1.2. Current Status of Development
      • 5.8.3.1.3. Clinical Studies
      • 5.8.3.1.4. Clinical Trial End-Point Analysis
• 5.9. Microbiome Therapeutics Developers: Companies with Maximum Number of Therapeutic Programs
• 5.10. 4D Pharma
  • 5.10.1. Company Overview
  • 5.10.2. Financial Information
  • 5.10.3. Microbiome-based Drug Portfolio
  • 5.10.4. Recent Developments and Future Outlook
• 5.11. Biosortia Pharmaceuticals
  • 5.11.1. Company Overview
  • 5.11.2. Microbiome-based Drug Portfolio
  • 5.11.3. Recent Developments and Future Outlook
• 5.12. Qu Biologics
  • 5.12.1. Company Overview
  • 5.12.2. Microbiome-based Drug Portfolio
  • 5.12.3. Recent Developments and Future Outlook
• 5.13. Servatus
  • 5.13.1. Company Overview
  • 5.13.2. Microbiome-based Drug Portfolio
  • 5.13.3. Recent Developments and Future Outlook

6. CLINICAL TRIAL ANALYSIS: HUMAN MICROBIOME THERAPEUTICS

• 6.1. Chapter Overview
• 6.2. Human Microbiome Therapeutics: List of Clinical Trials
  • 6.2.1. Analysis by Trial Status
  • 6.2.2. Analysis by Trial Registration Year
  • 6.2.3. Analysis by Trial Registration Year and Type of Study
  • 6.2.4. Analysis by Trial Phase and Trial Status
  • 6.2.5. Year-wise Trend of Completed and Recruiting Trials
  • 6.2.6. Analysis by Study Design
  • 6.2.7. Analysis by Patient Enrollment
  • 6.2.8. Analysis by Age Category
  • 6.2.9. Analysis by Type of Sponsor / Collaborator
  • 6.2.10. Most Active Industry Players: Analysis by Number of Registered Trials
  • 6.2.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
  • 6.2.12. Analysis by Trial Location
  • 6.2.13. Analysis by Trial Status and Geography

7. MICROBIOME DIAGNOSTICS AND SCREENING / PROFILING TESTS: MARKET LANDSCAPE

• 7.1. Chapter Overview
• 7.2. Overview of Microbiome Diagnostics and Screening / Profiling Tests
• 7.3. Microbiome Diagnostics and Screening / Profiling Tests: Marketed and Under Development Products
  • 7.3.1. Analysis by Stage of Development
  • 7.3.2. Analysis by Type of Test
  • 7.3.3. Analysis by Stage of Development and Type of Test
  • 7.3.4. Analysis by Type of Sample Analyzed
  • 7.3.5. Analysis by Type of Screening Technique
  • 7.3.6. Analysis by Target Indication
  • 7.3.7. Analysis by Therapeutic Area
  • 7.3.8. Analysis by Purpose of Test
• 7.4. Microbiome Diagnostic and Screening / Profiling Tests Providers
  • 7.4.1. Analysis by Year of Establishment
  • 7.4.2. Analysis by Company Size
  • 7.4.3. Analysis by Location of Headquarters
  • 7.4.4. Analysis by Company Size and Location of Headquarters

8. MICROBIOME DIAGNOSTIC AND SCREENING / PROFILING TEST PROVIDERS: COMPANY PROFILES

• 8.1. Chapter Overview
• 8.2. Shoreline Biome
  • 8.2.1. Company Overview
  • 8.2.2. Microbiome Test Portfolio
  • 8.2.3. Recent Developments and Future Outlook
• 8.3. DNA Genotek
  • 8.3.1. Company Overview
  • 8.3.2. Microbiome Test Portfolio
  • 8.3.3. Recent Developments and Future Outlook
• 8.4. Invivo Healthcare
  • 8.4.1. Company Overview
  • 8.4.2. Microbiome Test Portfolio
  • 8.4.3. Recent Developments and Future Outlook
• 8.5. GoodGut
  • 8.5.1. Company Overview
  • 8.5.2. Microbiome Test Portfolio
  • 8.5.3. Recent Developments and Future Outlook
• 8.6. BiomeDx
  • 8.6.1. Company Overview
  • 8.6.2. Microbiome Test Portfolio
  • 8.6.3. Recent Developments and Future Outlook

9. FECAL MICROBIOTA THERAPY (FMT)

• 9.1. Chapter Overview
• 9.2. Introduction to Fecal Microbiota Therapies (FMT)
• 9.3. Historical Overview
• 9.4. Fecal Microbiota Therapies: Procedure and Clinical Relevance
  • 9.4.1. Donor Selection
  • 9.4.2. Administration Procedure
  • 9.4.3. Routes of Administration
  • 9.4.4. Consequences and Adverse Events
  • 9.4.5. Clinical Guidelines Associated with FMT
• 9.5. Regulatory Guidelines Related to Fecal Microbiota Therapies
• 9.6. Insurance Coverage for Fecal Microbiota Therapies
• 9.7. Fecal Microbiota Therapies: Marketed and Development Pipeline
  • 9.7.1. Analysis by Application Area
  • 9.7.2. Analysis by Status of Development
  • 9.7.3. Analysis by Target Indication
  • 9.7.4. Analysis by Therapeutic Area
  • 9.7.5. Analysis by Route of Administration
  • 9.7.6. Fecal Microbiota Therapies: List of Developers
    • 9.7.6.1. Analysis by Year of Establishment
    • 9.7.6.2. Analysis by Company Size
    • 9.7.6.3. Analysis by Location of Headquarters

10. CLINICAL TRIALS ANALYSIS: FECAL MICROBIOTA THERAPY

• 10.1. Chapter Overview
• 10.2. Scope and Methodology
• 10.3. Fecal Microbiota Therapies: Clinical Trial Analysis
  • 10.3.1. Analysis by Trial Status
  • 10.3.2. Analysis by Trial Registration Year
  • 10.3.3. Analysis by Trial Recruitment Status
  • 10.3.4. Analysis by Trial Phase and Number of Patients Enrolled
  • 10.3.5. Analysis by Study Design
  • 10.3.6. Leading Industry Players: Analysis by Number of Registered Trials
  • 10.3.7. Leading Non-industry Players: Analysis by Number of Registered Trials
  • 10.3.8. Analysis by Trial Location
  • 10.3.9. Analysis by Trial Status and Geography

11. ATTRACTIVENESS COMPETITIVENESS (AC) MATRIX

• 11.1. Chapter Overview
• 11.2. AC Matrix: An Overview
  • 11.2.1. Strong Business Units
  • 11.2.2. Average Business Units
  • 11.2.3. Weak Business Units
• 11.3. AC Matrix: Analytical Methodology
• 11.4. AC Matrix: Plotting the Information
• 11.5. AC Matrix: Analyzing the Data
  • 11.5.1. Strong Business Units
  • 11.5.2. Average Business Units
  • 11.5.3. Weak Business Units
• 11.6. Concluding Remarks

12. MICROBIOME RELATED INITIATIVES OF BIG PHARMA PLAYERS

• 12.1. Chapter Overview
• 12.2. Scope and Methodology
• 12.3. Initiatives of Big Pharma Players
  • 12.3.1. Analysis by Portfolio Diversity
  • 12.3.2. Analysis by Phase of Development
  • 12.3.3. Analysis by Type of Molecule
  • 12.3.4. Analysis by Type of Therapy
  • 12.3.5. Analysis by Diversity of Therapeutic Areas
• 12.4. Benchmarking Analysis of Big Pharma Players
  • 12.4.1. Spider Web Analysis: Company A
  • 12.4.2. Spider Web Analysis: Company B
  • 12.4.3. Spider Web Analysis: Company C
  • 12.4.4. Spider Web Analysis: Company D
  • 12.4.5. Spider Web Analysis: Company E
  • 12.4.6. Spider Web Analysis: Company F
  • 12.4.7. Spider Web Analysis: Company G
  • 12.4.8. Spider Web Analysis: Company H
  • 12.4.9. Spider Web Analysis: Company I
  • 12.4.10. Spider Web Analysis: Company J
  • 12.4.11. Spider Web Analysis: Company K

13. START-UP HEALTH INDEXING

• 13.1. Chapter Overview
• 13.2. Scope and Methodology
• 13.3. Benchmarking of Start-ups
  • 13.3.1. Analysis by Portfolio Diversity
  • 13.3.2. Analysis by Phase of Development
  • 13.3.3. Analysis by Diversity in Indication
  • 13.3.4. Analysis by Funding Amount
  • 13.3.5. Analysis by Partnership Activity
  • 13.3.6. Start-up Health Indexing: Roots Analysis Perspective
  • 13.3.7. Start-up Health Indexing: Top Five Start-ups

14. KEY THERAPEUTIC AREAS

• 14.1. Chapter Overview
• 14.2. Metabolic Disorders
  • 14.2.1. Diabetes
    • 14.2.1.1. Disease Description
    • 14.2.1.2. Associated Health Risks / Complications
    • 14.2.1.3. Epidemiology
    • 14.2.1.4. Disease Diagnosis
    • 14.2.1.5. Current Treatment Options
      • 14.2.1.5.1. Insulin Therapies
      • 14.2.1.5.2. Non-Insulin Therapies
    • 14.2.1.6. Side Effects of Current Treatment Options
    • 14.2.1.7. Microbiome Therapeutics for Diabetes
  • 14.2.2. Lactose Intolerance
    • 14.2.2.1. Disease Description
    • 14.2.2.2. Epidemiology
    • 14.2.2.3. Current Treatment Options
    • 14.2.2.4. Microbiome Therapeutics for Lactose Intolerance
  • 14.2.3. Nonalcoholic Steatohepatitis (NASH)
    • 14.2.3.1. Disease Description
    • 14.2.3.2. Epidemiology
    • 14.2.3.3. Current Treatment Options
    • 14.2.3.4. Microbiome Therapeutics for NASH
  • 14.2.4. Primary Hyperoxaluria
    • 14.2.4.1. Disease Description
    • 14.2.4.2. Epidemiology
    • 14.2.4.3. Current Treatment Options
    • 14.2.4.4. Microbiome Therapeutics for Primary Hyperoxaluria
  • 14.2.5. Obesity
    • 14.2.5.1. Disease Description
    • 14.2.5.2. Epidemiology
    • 14.2.5.3. Current Treatment Options
    • 14.2.5.4. Side Effects of Current Treatment Options
    • 14.2.5.5. Microbiome Therapeutics for Obesity
• 14.3. Digestive and Gastrointestinal Disorders
  • 14.3.1. Crohn's Disease
    • 14.3.1.1. Disease Description
    • 14.3.1.2. Epidemiology
    • 14.3.1.3. Current Treatment Options
    • 14.3.1.4. Side Effects of Current Treatment Options
    • 14.3.1.5. Microbiome Therapeutics for Crohn's Disease
  • 14.3.2. Irritable Bowel Syndrome (IBS)
    • 14.3.2.1. Disease Description
    • 14.3.2.2. Epidemiology
    • 14.3.2.3. Current Treatment Options
    • 14.3.2.4. Microbiome Therapeutics for IBS
  • 14.3.3. Ulcerative Colitis
    • 14.3.3.1. Disease Description
    • 14.3.3.2. Epidemiology
    • 14.3.3.3. Current Treatment Options
    • 14.3.3.4. Side Effects of Current Treatment Options
    • 14.3.3.5. Microbiome Therapeutics for Ulcerative Colitis
• 14.4. Oncological Indications
  • 14.4.1. Colorectal Cancer
    • 14.4.1.1. Disease Description
    • 14.4.1.2. Epidemiology
    • 14.4.1.3. Current Treatment Options
    • 14.4.1.4. Side Effects of Current Treatments
    • 14.4.1.5. Microbiome Therapeutics for Colorectal Cancer
  • 14.4.2. Lung Cancer
    • 14.4.2.1. Disease Description
    • 14.4.2.2. Epidemiology
    • 14.4.2.3. Current Treatment Options
    • 14.4.2.4. Side Effects of Current Treatment Options
    • 14.4.2.5. Microbiome Therapeutics for Lung Cancer
• 14.5. Dermatological Disorders
  • 14.5.1. Acne Vulgaris
    • 14.5.1.1. Disease Description
    • 14.5.1.2. Epidemiology
    • 14.5.1.3. Current Treatment Options
    • 14.5.1.4. Side Effects of Current Treatment Options
    • 14.5.1.5. Microbiome Therapeutics for Acne Vulgaris
• 14.6. Infectious Diseases
  • 14.6.1. Clostridium Difficile Infections (CDIs)
    • 14.6.1.1. Disease Description
    • 14.6.1.2. Epidemiology
    • 14.6.1.3. Disease Diagnosis
    • 14.6.1.4. Current Treatment Options
    • 14.6.1.5. Side Effects of Current Treatment Options
    • 14.6.1.6. Microbiome Therapeutics for CDI
  • 14.6.2. Bacterial Vaginosis
    • 14.6.2.1. Disease Description
    • 14.6.2.2. Epidemiology
    • 14.6.2.3. Current Treatment Options
    • 14.6.2.4. Side Effects of Current Treatment Options
    • 14.6.2.5. Microbiome Therapeutics for Bacterial Vaginosis

15. PARTNERSHIPS AND COLLABORATIONS

• 15.1. Chapter Overview
• 15.2. Partnership Models
• 15.3. Human Microbiome: List of Partnerships and Collaborations
• 15.4. Analysis by Year of Partnership
• 15.5. Analysis by Type of Partnership
• 15.6. Analysis by Year and Type of Partnership
• 15.7. Analysis by Type of Product
• 15.8. Analysis by Target Indication
• 15.9. Analysis by Therapeutic Area
• 15.10. Analysis by Type of Company
• 15.11. Analysis by Type of Partner
• 15.12. Most Active Players: Analysis by Number of Partnerships
• 15.13. Intercontinental and Intracontinental Agreements

16. FUNDING AND INVESTMENT ANALYSIS

• 16.1. Chapter Overview
• 16.2. Types of Funding
• 16.3. Microbiome Therapeutics and Diagnostics: List of Funding and Investments
  • 16.3.1. Analysis by Year of Investment
  • 16.3.2. Analysis by Amount Invested
  • 16.3.3. Analysis by Type of Funding
  • 16.3.4. Analysis by Type of Company
  • 16.3.5. Analysis by Purpose of Funding
  • 16.3.6. Analysis by Type of Product
  • 16.3.7. Analysis by Target Indication
  • 16.3.8. Analysis by Therapeutic Area
  • 16.3.9. Analysis by Geography
  • 16.3.10. Most Active Players: Analysis by Number of Instances
  • 16.3.11. Most Active Players: Analysis by Amount Invested
  • 16.3.12. Most Active Investors: Analysis by Number of Instances
  • 16.3.13. Funding and Investment Summary

17. CASE STUDY: CONTRACT SERVICES FOR MICROBIOME THERAPEUTICS AND LIVE BIOTHERAPEUTICS

• 17.1. Chapter Overview
• 17.2. Manufacturing Microbiome Therapeutics
  • 17.2.1. Key Steps Involved
  • 17.2.2. Associated Challenges
  • 17.2.3. Growing Demand for Contract Manufacturing Services
  • 17.2.4. Contract Manufacturing Organizations (CMOs)
    • 17.2.4.1. Introduction to Contract Manufacturing
  • 17.2.5. Microbiome Therapeutics: List of Contract Manufacturing Providers
    • 17.2.5.1. Analysis by Year of Establishment
    • 17.2.5.2. Analysis by Company Size
    • 17.2.5.3. Analysis by Location of Headquarters
    • 17.2.5.4. Analysis by Scale of Operation
    • 17.2.5.5. Analysis by Type of Product Manufactured
    • 17.2.5.6. Analysis by Type of Formulation
    • 17.2.5.7. Analysis by Scale of Operation and Type of Formulation
• 17.3. Key Considerations for Selecting a CMO / CRO Partner

18. BIG DATA AND MICROBIOME THERAPEUTICS

• 18.1. Chapter Overview
• 18.2. Introduction to Big Data
• 18.3. Internet of Things (IoT)
• 18.4. Growing Interest in Big Data: Google Trends Analysis
• 18.5. Key Application Areas
• 18.6. Big Data in Microbiome Research
  • 18.6.1. Microbiome Data and Personalized Medicine
  • 18.6.2. Microbiome-related Data Management Challenges
  • 18.6.3. National Microbiome Data Center
• 18.7. Big Data Services for Microbiome Research: List of Companies
• 18.8. Big Data Services for Microbiome Research: Profiles of Key Players
  • 18.8.1. Human Longevity
    • 18.8.1.1. Company Overview
    • 18.8.1.2. Technology and Service Portfolio
    • 18.8.1.3. Recent Developments and Future Outlook
  • 18.8.2. Resilient Biotics
    • 18.8.2.1. Company Overview
    • 18.8.2.2. Technology and Service Portfolio
    • 18.8.2.3. Recent Developments and Future Outlook
  • 18.8.3. Resphera Biosciences
    • 18.8.3.1. Company Overview
    • 18.8.3.2. Technology and Service Portfolio
    • 18.8.3.3. Recent Developments and Future Outlook

19. MICROBIOME THERAPEUTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS

• 19.1. Chapter Overview
• 19.2. Key Assumptions
• 19.3. Forecast Methodology
• 19.4. Global Microbiome Therapeutics Market, Till 2035
  • 19.4.1. Microbiome Therapeutics Market: Distribution by Type of Product Till 2035
    • 19.4.1.1. Microbiome Therapeutics Market for Probiotic Drugs, Till 2035
    • 19.4.1.2. Microbiome Therapeutics Market for Other Drugs, Till 2035
  • 19.4.2. Microbiome Therapeutics Market: Distribution by Target Disease Indication, Till 2035
    • 19.4.2.1. Microbiome Therapeutics Market for Graft Versus Host Disease, Till 2035
    • 19.4.2.2. Microbiome Therapeutics Market for Necrotizing Enterocolitis, Till 2035
    • 19.4.2.3. Microbiome Therapeutics Market for Primary Hyperoxaluria, Till 2035
    • 19.4.2.4. Microbiome Therapeutics Market for Recurrent C. difficile Infection, Till 2035
  • 19.4.3. Microbiome Therapeutics Market: Distribution by Therapeutic Area, Till 2035
    • 19.4.3.1. Microbiome Therapeutics Market for Digestive and Gastrointestinal Disorders, Till 2035
    • 19.4.3.2. Microbiome Therapeutics Market for Infectious Diseases, Till 2035
    • 19.4.3.3. Microbiome Therapeutics Market for Rare Disorders, Till 2035
  • 19.4.4. Microbiome Therapeutics Market: Route of Administration, Till 2035
    • 19.4.4.1. Microbiome Therapeutics Market for Oral Therapeutics, Till 2035
    • 19.4.4.2. Microbiome Therapeutics Market for Rectal Therapeutics, Till 2035
  • 19.4.5. Microbiome Therapeutics Market: Distribution by Type of Formulation, Till 2035
    • 19.4.5.1. Microbiome Therapeutics Market for Capsules, Till 2035
    • 19.4.5.2. Microbiome Therapeutics Market for Suspensions, Till 2035
    • 19.4.5.3. Microbiome Therapeutics Market for Enemas, Till 2035
  • 19.4.6. Microbiome Therapeutics Market: Distribution by Key Geographical Regions, Till 2035
    • 19.4.6.1. Microbiome Therapeutics Market in North America, Till 2035
    • 19.4.6.2. Microbiome Therapeutics Market in Europe, Till 2035
    • 19.4.6.3. Microbiome Therapeutics Market in Asia-Pacific and Rest of the World, Till 2035
  • 19.4.7. Microbiome Therapeutics Market: Distribution by Leading Drug Developers, Till 2035
  • 19.4.8. Microbiome Therapeutics Market: Distribution by Leading Therapeutic Products, Till 2035
    • 19.4.8.1. SER-109 (Seres Therapeutics)
    • 19.4.8.2. RBX2660 (ReBiotix)
    • 19.4.8.3. CP101 (Finch Therapeutics)
    • 19.4.8.4. IBP-9414 (Infant bacterial Therapeutics)
    • 19.4.8.5. Oxabact (OxThera)
    • 19.4.8.6. MaaT013 (MaaT Pharma)

20. MICROBIOME DIAGNOSTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS

• 20.1. Chapter Overview
• 20.2. Scope and Limitations
• 20.3. Forecast Methodology
• 20.4. Global Human Microbiome Diagnostic Test Market, Till 2035
  • 20.4.1. Human Microbiome Diagnostic Tests Market by Target Indication
    • 20.4.1.1. Human Microbiome Diagnostic Tests Market for Inflammatory Bowel Syndrome, Till 2035
    • 20.4.1.2. Human Microbiome Diagnostic Tests Market for Irritable Bowel Disease, Till 2035
    • 20.4.1.3. Human Microbiome Diagnostic Tests Market for Colorectal Cancer, Till 2035
    • 20.4.1.4. Human Microbiome Diagnostic Tests Market for Diabetes Mellitus, Till 2035
  • 20.4.2. Human Microbiome Diagnostic Tests Market: Distribution by Therapeutic Area
    • 20.4.2.1. Human Microbiome Diagnostic Tests Market for Digestive and Gastrointestinal Disorders, Till 2035
    • 20.4.2.2. Human Microbiome Diagnostic Tests Market for Oncological Disorders, Till 2035
    • 20.4.2.3. Human Microbiome Diagnostic Tests Market for Metabolic Disorders, Till 2035
  • 20.4.3. Human Microbiome Diagnostic Tests Market: Distribution by Key Geographical Regions
    • 20.4.3.1. Human Microbiome Diagnostic Tests Market in North America, Till 2035
    • 20.4.3.2. Human Microbiome Diagnostic Tests Market in Europe, Till 2035
    • 20.4.3.3. Human Microbiome Diagnostic Tests Market in Asia Pacific, Till 2035

21. FECAL MICROBIOTA THERAPIES: MARKET FORECAST AND OPPORTUNITY ANALYSIS

• 21.1. Chapter Overview
• 21.2. Forecast Methodology and Key Assumptions
• 21.3. Global Fecal Microbiota Therapies Market, Till 2035
  • 21.3.1. Global Fecal Microbiota Therapies Market, Till 2035 (By Value)
  • 21.3.2. Global Fecal Microbiota Therapies Market, Till 2035 (By Value)
  • 21.3.3. Overall FMT Market, Till 2035 (By Volume)
• 21.4. Overall Microbiome Market by Product Offerings, Till 2035

22. CASE STUDY: MICROBIOME-BASED PRODUCTS IN NON-PHARMACEUTICAL INDUSTRIES

• 22.1. Chapter Overview
• 22.2. List of Microbiome Products in Non-Pharmaceutical Industry
  • 22.2.1. Applications of Microbiome Based Products in Cosmetics and Food Industry
• 22.3. Applications of Microbiome Based Products in Agriculture Industry
• 22.4. Future Perspectives

23. CONCLUDING REMARKS

24. EXECUTIVE INSIGHTS

• 24.1. Chapter Overview
• 24.2. Company A
  • 24.2.1. Company / Organization Snapshot
  • 24.2.2. Interview Transcript: Senior Manager, Corporate Development
• 24.3. Company B
  • 24.3.1. Company / Organization Snapshot
  • 24.3.2. Interview Transcript: Co-founder and Chairman
• 24.4. Company C
  • 24.4.1. Company / Organization Snapshot
  • 24.4.2. Interview Transcript: Chief Executive Officer
• 24.5. Company D
  • 24.5.1. Company / Organization Snapshot
  • 24.5.2. Interview Transcript: Senior Scientist
• 24.6. Company E
  • 24.6.1. Company / Organization Snapshot
  • 24.6.2. Interview Transcript: Associate General Manager
• 24.7. Company F
  • 24.7.1. Company / Organization Snapshot
  • 24.7.2. Interview Transcript: Ex-Vice President, Business Development
• 24.8. Company G
  • 24.8.1. Company / Organization Snapshot
  • 24.8.2. Interview Transcript: Chief Business Officer
• 24.9. Company H
  • 24.9.1. Company / Organization Snapshot
  • 24.9.2. Interview Transcript: Ex-Vice President, Sales and Business Development
• 24.10. Company I
  • 24.10.1. Company / Organization Snapshot
  • 24.10.2. Interview Transcript: Co-founder and Chief Executive Officer
• 24.11. Company J
  • 24.11.1. Company / Organization Snapshot
  • 24.11.2. Interview Transcript: Co-founder and Chief Executive Officer
• 24.12. Company K
  • 24.12.1. Company / Organization Snapshot
  • 24.12.2. Interview Transcripts: Co-founder and Chief Executive Officer
• 24.13. Company L
  • 24.13.1. Company / Organization Snapshot
  • 24.13.2. Interview Transcripts: Ex-Co-founder and Vice President of Innovation
• 24.14. Company M
  • 24.14.1. Company / Organization Snapshot
  • 24.14.2. Interview Transcript: Vice President, Business Development and Marketing
• 24.15. Company N
  • 24.15.1. Company / Organization Snapshot
  • 24.15.2. Interview Transcript: Ex-Vice President, Operations
• 24.16. Company O
  • 24.16.1. Company / Organization Snapshot
  • 24.16.2. Interview Transcript: President and Chief Executive Officer
• 24.17. Company P
  • 24.17.1. Company / Organization Snapshot
  • 24.17.2. Interview Transcript: Ex-Chief Scientific Officer and Vice President
• 24.18. Company Q
  • 24.18.1. Company / Organization Snapshot
  • 24.18.2. Interview Transcript: Chief Strategy Officer

25. APPENDIX I: TABULATED DATA

26. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

관련자료